Karyopharm Therapeutics Inc.
KPTI
$1.62
-$0.08-4.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.81% | 6.33% | 0.57% | -3.98% | -5.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.81% | 6.33% | 0.57% | -3.98% | -5.77% |
| Cost of Revenue | -10.46% | -11.52% | -11.84% | -11.85% | -8.21% |
| Gross Profit | 530.84% | 456.90% | 462.34% | 177.97% | 48.43% |
| SG&A Expenses | -7.84% | -7.69% | -8.86% | -7.83% | -9.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.31% | -9.86% | -10.54% | -10.11% | -8.73% |
| Operating Income | 28.52% | 29.20% | 24.06% | 17.33% | 12.02% |
| Income Before Tax | -81.90% | -211.94% | -156.66% | -42.94% | -37.86% |
| Income Tax Expenses | -540.00% | -63.64% | -24.56% | -99.66% | -101.79% |
| Earnings from Continuing Operations | -81.88% | -211.84% | -156.52% | -42.46% | -37.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.88% | -211.84% | -156.52% | -42.46% | -37.43% |
| EBIT | 28.52% | 29.20% | 24.06% | 17.33% | 12.02% |
| EBITDA | 28.46% | 29.19% | 24.09% | 17.39% | 12.04% |
| EPS Basic | 11.94% | -85.32% | -77.08% | -30.34% | -23.13% |
| Normalized Basic EPS | 35.79% | 11.60% | 12.19% | 12.80% | 16.05% |
| EPS Diluted | 10.40% | -13.81% | -13.69% | 11.20% | 14.57% |
| Normalized Diluted EPS | 36.55% | 8.50% | 8.79% | 9.79% | 13.27% |
| Average Basic Shares Outstanding | 129.24% | 71.96% | 34.36% | 7.54% | 8.93% |
| Average Diluted Shares Outstanding | 137.23% | 68.79% | 25.75% | 0.50% | 1.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |